Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Similar articles for PubMed (Select 23125078)

1.

Nkx2-1: a novel tumor biomarker of lung cancer.

Yang L, Lin M, Ruan WJ, Dong LL, Chen EG, Wu XH, Ying KJ.

J Zhejiang Univ Sci B. 2012 Nov;13(11):855-66. doi: 10.1631/jzus.B1100382. Review.

2.

Metabolomics a novel biomarker in lung cancer.

Stinkens K, Vanhove K, Thomeer M.

J Thorac Oncol. 2015 Jun;10(6):e46. doi: 10.1097/JTO.0000000000000502. No abstract available.

PMID:
26001150
3.

[Research progress of thyroid transcription factor-1 as molecular marker in lung carcinoma].

Ge X, Jiang L.

Zhongguo Fei Ai Za Zhi. 2014 Jun 20;17(6):491-5. doi: 10.3779/j.issn.1009-3419.2014.06.10. Review. Chinese.

4.

Warranting investigation of primary lung adenocarcinoma in patients with an extrapulmonary malignancy and lung nodules due to high frequency.

Zhu B, Dalal S, Kamp DW, Lin X.

Am J Clin Pathol. 2014 Mar;141(3):429-36. doi: 10.1309/AJCP97FTJXWPFJXY.

5.

The complexity of thyroid transcription factor 1 with both pro- and anti-oncogenic activities.

Mu D.

J Biol Chem. 2013 Aug 30;288(35):24992-5000. doi: 10.1074/jbc.R113.491647. Epub 2013 Jul 1. Review.

6.

NKX2-1/TTF-1: an enigmatic oncogene that functions as a double-edged sword for cancer cell survival and progression.

Yamaguchi T, Hosono Y, Yanagisawa K, Takahashi T.

Cancer Cell. 2013 Jun 10;23(6):718-23. doi: 10.1016/j.ccr.2013.04.002. Review.

7.

[Proteome profiling for the identification of lung cancer signatures].

Cho WC.

Zhongguo Fei Ai Za Zhi. 2012 Jul 20;15(7):C4-7. doi: 10.3779/j.issn.1009-3419.2012.07.11. Chinese. No abstract available.

8.

Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma.

Snyder EL, Watanabe H, Magendantz M, Hoersch S, Chen TA, Wang DG, Crowley D, Whittaker CA, Meyerson M, Kimura S, Jacks T.

Mol Cell. 2013 Apr 25;50(2):185-99. doi: 10.1016/j.molcel.2013.02.018. Epub 2013 Mar 21.

9.

MicroRNA-365 regulates NKX2-1, a key mediator of lung cancer.

Kang SM, Lee HJ, Cho JY.

Cancer Lett. 2013 Jul 28;335(2):487-94. doi: 10.1016/j.canlet.2013.03.006. Epub 2013 Mar 16.

PMID:
23507558
10.

Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target.

Watanabe H, Francis JM, Woo MS, Etemad B, Lin W, Fries DF, Peng S, Snyder EL, Tata PR, Izzo F, Schinzel AC, Cho J, Hammerman PS, Verhaak RG, Hahn WC, Rajagopal J, Jacks T, Meyerson M.

Genes Dev. 2013 Jan 15;27(2):197-210. doi: 10.1101/gad.203208.112. Epub 2013 Jan 15.

11.

Thyroid transcription factor 1 and Napsin A double stain: utilizing different vendor antibodies for diagnosing lung adenocarcinoma.

Johnson H, Cohen C, Fatima N, Duncan D, Siddiqui MT.

Acta Cytol. 2012;56(6):596-602. doi: 10.1159/000339793. Epub 2012 Nov 24.

PMID:
23207437
12.

A pilot characterization of human lung NSCLC by protein pathway activation mapping.

Zupa A, Improta G, Silvestri A, Pin E, Deng J, Aieta M, Musto P, Nitti D, Mammano E, Liotta L, Belluco C, Wulfkuhle J, Petricoin E 3rd.

J Thorac Oncol. 2012 Dec;7(12):1755-66. doi: 10.1097/JTO.0b013e3182725fc7.

PMID:
23154546
13.

[Diagnosis value of serum NKX2-1 for primary lung cancer].

Yang L, Ruan WJ, Chen EG, Ying KJ.

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2012 Sep;41(5):535-9. Chinese.

PMID:
23086646
14.

Renal metastasis from pulmonary adenocarcinoma: the pathologist's approach to an uncommon finding: case report and review of the literature.

Scatena C, Comin CE, Lapini A, Raspollini MR.

Appl Immunohistochem Mol Morphol. 2013 Oct;21(5):460-3. doi: 10.1097/PAI.0b013e31827101b1. Review.

PMID:
23060303
15.

Best immunohistochemical panel in distinguishing adenocarcinoma from squamous cell carcinoma of lung: tissue microarray assay in resected lung cancer specimens.

Kim MJ, Shin HC, Shin KC, Ro JY.

Ann Diagn Pathol. 2013 Feb;17(1):85-90. doi: 10.1016/j.anndiagpath.2012.07.006. Epub 2012 Oct 4.

PMID:
23040737
16.

Negative NKX2-1 (TTF-1) as temporary surrogate marker for treatment selection during EGFR-mutation analysis in patients with non-small-cell lung cancer.

Vincenten J, Smit EF, Vos W, Gr├╝nberg K, Postmus PE, Heideman DA, Snijders PJ, Meijer G, Kuik J, Witte BI, Thunnissen E.

J Thorac Oncol. 2012 Oct;7(10):1522-7. doi: 10.1097/JTO.0b013e3182635a91.

PMID:
22982653
17.

Thyroid transcription factor 1 represses the expression of Ki-67 and induces apoptosis in non-small cell lung cancer.

Zu YF, Wang XC, Chen Y, Wang JY, Liu X, Li X, Li CW, Xie YC, Luo Y, Shang XQ, Guo J.

Oncol Rep. 2012 Nov;28(5):1544-50. doi: 10.3892/or.2012.2009. Epub 2012 Aug 31.

18.

Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies.

Warth A, Muley T, Herpel E, Meister M, Herth FJ, Schirmacher P, Weichert W, Hoffmann H, Schnabel PA.

Histopathology. 2012 Dec;61(6):1017-25. doi: 10.1111/j.1365-2559.2012.04308.x. Epub 2012 Aug 8.

PMID:
22882703
19.

Thyroid transcription factor 1 and napsin a double staining in lung adenocarcinoma in pleural fluid.

Liu L, Cohen C, Siddiqui MT.

Acta Cytol. 2012;56(4):425-30. doi: 10.1159/000337439. Epub 2012 Jul 25.

PMID:
22846220
20.

Occludin is a direct target of thyroid transcription factor-1 (TTF-1/NKX2-1).

Runkle EA, Rice SJ, Qi J, Masser D, Antonetti DA, Winslow MM, Mu D.

J Biol Chem. 2012 Aug 17;287(34):28790-801. doi: 10.1074/jbc.M112.367987. Epub 2012 Jul 2.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk